Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSPO | P30536 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5416391 | 0.88 | TSPO (0.52) | TSPO | |
| SCHEMBL5427111 | 0.81 | TSPO (0.51) | TSPO | |
| SCHEMBL5422155 | 0.78 | TSPO (0.53) | TSPO | |
| SCHEMBL5424183 | 0.75 | TSPO (0.51) | TSPO | |
| SCHEMBL5416490 | 0.75 | TSPO (0.51) | TSPO | |
| SCHEMBL5418860 | 0.71 | TSPO (0.67) | TSPO | |
| SCHEMBL5412367 | 0.71 | TSPO (0.80) | TSPO | |
| SCHEMBL5424995 | 0.69 | TSPO (0.59) | TSPO | |
| SCHEMBL5411227 | 0.69 | TSPO (0.57) | TSPO | |
| SCHEMBL5427489 | 0.68 | TSPO (0.52) | TSPO |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070191447-A1 | Novel heterocyclic compound | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2007-08-16 | — | — | US | disclosed |
| CN-1922141-A | Novel heterocyclic compound | DAINIPPON SUMITOMO PHARMA CO (JP) | 2007-02-28 | — | — | CN | disclosed |
| EP-1719761-A1 | NOVEL HETEROCYCLIC COMPOUND | Dainippon Sumitomo Pharma Co., Ltd. (JP) | 2006-11-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070191447-A1 | Novel heterocyclic compound | OPRD1, GRIN3A, GRM3 | TSPO 166/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.